Quanterix Expands Headquarters to New, State-Of-The-Art Facility in Billerica, Mass. As Demand Continues to Grow for Its Disruptive Simoa Platforms

World-class facility will offer the Company nearly three times the space for disruptive biomarker technology innovation and to accommodate growing pharma services business

Billerica, Mass. – May 29, 2019 — Quanterix Corporation (NASDAQ:QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, today announced the relocation of its headquarters to a brand new, state-of-the-art facility in Billerica, Mass. Brought on by Quanterix’ rapid growth, the move will allow the Company to unite its CLIA-certified laboratory with its expanding workforce to accelerate entry into pharmaceutical drug services and further increase its impact on the transformation of precision healthcare.

“We experienced considerable success in our former facilities, launching several new biomarker technologies that are beginning to disrupt drug development and drug approval methodologies, acquiring Aushon to accelerate our entry into Biopharma services and leading a successful public offering in December 2017,” said Kevin Hrusovsky, Chairman and CEO, Quanterix. “These advancements, coupled with the rapid adoption of ultrasensitive protein biomarkers as critical tools for drug development, next generation diagnostics discovery and early disease detection health screens, have fueled our growth and heightened our enthusiasm for the future. As we expand, we’re happy to keep our headquarters in the greater Boston area, a center for medical innovation and a compelling location for Quanterix to lead its global quest to revolutionize healthcare utilizing digital biomarker innovations.”

The two story, 92,000 square-foot space features new offices and expanded manufacturing and laboratory space. By bringing all business operations together under the same roof as its CLIA-certified lab and Accelerator Lab providing services to BioPharma, Quanterix is able to offer customers a single home for all of its biomarker research needs across a wide range of therapeutic categories. Additionally, the space allows Quanterix to continue growing and innovating its technology bench and industry-leading ultrasensitive assay menu, as the pharmaceutical industry and medical community continue to put an emphasis on the importance of biomarker testing.

“Massachusetts remains a global hub for innovation and research, and our administration has prioritized efforts to create an environment that supports this important sector of our economy,” said Massachusetts Governor Charlie Baker. “Quanterix’ expansion is a great addition to the Commonwealth’s digital health ecosystem and we look forward to the opening of this new facility.”

Located at 900 Middlesex Turnpike in Billerica, Mass., the new headquarters will help the company continue to attract top talent to fuel its rapid growth and offers employees a world-class workplace designed to support collaboration, innovation, and inspiration. The move brings together employees from both its former Lexington and Billerica sites into a single facility, and the additional space will enable Quanterix to continue to grow its headcount, which increased by more than 40 percent in 2018 alone.

“The new space gives us the room and amenities to inspire our incredible team as they work to advance innovation and disrupt medicine. We’re excited to remain in Boston and have this “state of the art” workplace that we can call home, one that emulates our unique company culture and compelling mission of personalized precision health,” continued Hrusovsky.

About Quanterix

Quanterix is a company that’s digitizing biomarker analysis with the goal of advancing the science of precision health. The company’s digital health solution, Simoa, has the potential to change the way in which healthcare is provided today by giving researchers the ability to closely examine the continuum from health to disease. Quanterix’ technology is designed to enable much earlier disease detection, better prognoses and enhanced treatment methods to improve the quality of life and longevity of the population for generations to come. The technology is currently being used for research applications in several therapeutic areas, including oncology, neurology, cardiology, inflammation and infectious disease. The company was established in 2007 and is located in Billerica, Massachusetts. For additional information, please visit https://www.quanterix.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements in this news release are based on Quanterix’ expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Factors that may cause Quanterix’ actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Quanterix’ filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" sections contained therein. Except as required by law, Quanterix assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.